We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Arecor Therapeutics Plc | LSE:AREC | London | Ordinary Share | GB00BMWLM973 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 131.00 | 127.00 | 135.00 | 131.00 | 131.00 | 131.00 | 5,777 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 3.54M | -9.26M | -0.3024 | -4.33 | 40.12M |
Arecor Therapeutics plc
("Arecor" or the "Company")
BOARD CHANGE
ARECOR ANNOUNCES SUSAN LOWTHER TO STEP DOWN AS CHIEF FINANCIAL OFFICER
Cambridge, UK, 23 April 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announced that Susan Lowther has decided to step down from her role as Chief Financial Officer, Company Secretary and as a Board Director, to pursue new opportunities.
A search for Susan's successor is underway and her last day with Arecor is expected to be on the 22 July, to ensure an effective handover.
Sarah Howell, Chief Executive Officer of Arecor, said: "On behalf of the Board and all at Arecor, I want to thank Susan for her contributions over the past five years, in our transition to a public company and growth as a business. We wish her every success in her future plans."
Susan Lowther, Chief Financial Officer of Arecor, said: "I am proud to have been Arecor's first Chief Financial Officer and of our achievements as a business, and believe the Company is well placed for further growth. I will watch the future progress with interest."
-ENDS-
For more information, please contact:
Arecor Therapeutics plc |
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
Susan Lowther, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) |
|
Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
|
|
WG Partners LLP (Financial Advisor) |
|
Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang |
Tel: +44 (0)203 705 9321 |
|
|
ICR Consilium |
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com |
|
|
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
1 Year Arecor Therapeutics Chart |
1 Month Arecor Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions